News
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Current health news includes a push for board overhaul at Avantor by Engine Capital, Ab&B Bio-Tech's share surge during its ...
Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every ...
A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...
12h
GlobalData on MSNWeightWatchers shuns compounded semaglutide amid FDA rules
WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.
Reuters on MSN17h
Novo ramps up lawsuits over Wegovy copies - but not for Hims & Hers
In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
Researchers at Syracuse University have identified a brain peptide, TDN, that effectively curbs appetite and enhances glucose ...
Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
9h
Inquirer on MSNBattle of the bulge: Will China’s home-grown obesity drugs reshape global weight loss market?
Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...
A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results